Skip to main content

Table 1 Features of the studies included

From: Prognostic nutritional index and the prognosis of diffuse large b-cell lymphoma: a meta-analysis

Author Country Year Sample size (high/low PNI) Cut-off value of PNI Median (range) of PNI Adjusted factors Follow-up time (month) Age (year)(range) NOS score Treatment Stage Survival outcome
Xiaoxiao Hao China 2017 125/127 45 IPI, GPS, NLR, PNI, PI 49 (16–82) 6 R-CHOP;
CHOP/CHOP-like
I–IV OS, PFS
Wenjuan Yu China 2019 114/195 45 48.4 (23.9–86.2) BMI, hemoglobin,
NCCI-IPI
7 R-CHOP I–IV OS
Se-Il Go Korea 2019 69/159 40 Sarcopenia, albumin, ALC, BMI, IPI, B-symptoms 64 (21–88) 7 R-CHOP I–IV OS, PFS
Vlatka Periˇsa Croatia 2017 75/28 44.55 50.26 (22.91–65.3) Age, gender, IPI
ECOG-PS, LDH,
Ann Arbor stage,
B-symptoms
Median: 27 (range: 1–105) 63 (22–87) 6 R-CHOP/
R-CHOP-like
I–IV OS, PFS
Qinjun Zhou China 2016 129/124 44.675 - B-symptoms, LDH,
Ann Arbor stage,
ECOG-PS,
extra-nodal, IPI
49 (19–81) 6 R‑CHOP I–IV OS, PFS
Teng Song China 2019 44/38 44.15 ECOG-PS, Ann Arbor stage, LDH,IPI, ALC 59(23–79) 6 CHOP;
R-CHOP
I–IV OS
Erina
Hamada
Japan 2020 38/46 41.3 Albumin, ALC, IPI, extra-nodal
ECOG-PS, LDH, gender, Ann Arbor stage, B-symptoms
Median: 39 84 (80–94) 6 R-CHOP;
R-CVP; R alone; palliative
I–IV OS
  1. IPI International Prognostic Index, PNI Platelet Lymphocyte Ratio, PNI Prognostic Nutritional Index, GPS Glasgow prognostic score, PI Prognostic Index, NLR Neutrophil Lymphocyte Ratio, R-CHOP rituximab plus cyclophosphamide doxorubicin vincristine and prednisone, BMI Body Mass Index, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, PFS progression-free survival, OS overall survival, ALC Absolute lymphocyte count, NCCN National Comprehensive Cancer Network